Bohler J, Zauner I, Bach D, Braun N, Fauunfstuck R, Helmchen U, Schollmeyer P
Effect of initial histology and plasmapheresis treatment on prognosis in RPGN: results of the German prospective randomized multicenter study
Am Soc Nephrol
J Am Soc Nephrol (abstract) (Nov) 6:412 1995

In a prospective multicenter randomized study, 39 pts with biopsy-proven RPGN (non-anti-GBM) received either immunosuppressives (prednisone plus cyclophosphamide) (n=18) or immunosuppressives plus plasmapheresis (n=21). Patients were followed for 60 months or until renal or actual death. Plasmapheresis did not improve outcome. Glomerular sclerosis was a predictor of poor outcome. (Leehey)

To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
ARF etiology : Acute glomerulonephritis/RPGN
Other extracorporeal therapies : Plasmapheresis

The therapeutic benefit of extracorporeal plasmapheresis or better extracorporeal immunoadsorption is depend on a aggressive therapeutic schedule. We have treated successfully patients with FSGN and RPGN (Lupus nephritis, membranoproliferative GN, ANCA-pos. systemic Vasculitis with GN)with an aggressive extracorporeal immunoadsortpion ( Protein A, Anti-IgG )and a mild immunosuppressive drug therapy. The adsorbed plasmavolume/ treatment was higher than 10-12 ltr. For further information : Dialyse-Gemeinschaft Nord e.V. Institute for Nephrology and Hypertensive Diseases Rigaer Str. 21, DE-18107 Rostock Tel.: +49-381-4019907 +49-381-7768112 Fax : +49-381-4019908 Mail: dgn@dialysis-north.de Web : http://www.bioeng.de
Dr. Roland E. Winkler
Rostock, Mecklenburg-Vorpommern Germany-Monday, April 13, 1998 at 01:11:10 (PDT)